Clinical Trials
2 trialsNCT03233139 2026-02-12
Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced Malignancies
Regeneron Pharmaceuticals
Phase 1 Active not recruiting
NCT02520245 2016-11-07
Companion Study for Patients Who Completed Participation in a REGN2810 (Anti-PD-1) Clinical Study
Regeneron Pharmaceuticals
Phase 1 Withdrawn